Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TERT | O14746 | 1/20 | 0.36 |
| ▸ | PSMB5 | P28074 | 5/20 | 0.36 |
| ▸ | GPR139 | Q6DWJ6 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.30 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7055566 | 1.00 | TERT (0.36) | TERTPSMB5GPR139LMNACYP1A2 | |
| SCHEMBL27261910 | 0.86 | — | — | |
| SCHEMBL582963 | 0.86 | — | — | |
| SCHEMBL582962 | 0.86 | — | — | |
| SCHEMBL6576267 | 0.82 | TERT (0.35) | TERTPSMB5 | |
| SCHEMBL6576270 | 0.82 | TERT (0.35) | TERTPSMB5 | |
| SCHEMBL11761746 | 0.80 | PSMB5 (0.42) | TERTPSMB5 | |
| SCHEMBL9098350 | 0.76 | ACACB (0.36) | — | |
| SCHEMBL9098345 | 0.76 | ACACB (0.36) | — | |
| SCHEMBL24968735 | 0.76 | ALDH1A1 (0.39) | TERTPSMB5GPR139 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030212051-A1 | Bile acid containing prodrugs with enhanced bioavailabilty | UNIVERSITY OF MARYLAND, BALTIMORE | 2003-11-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030212051-A1 | Bile acid containing prodrugs with enhanced bioavailabilty | SLC10A2, SLC10A1, NR1H4 | TERT 4493/4885PSMB5 4563/4885GPR139 1188/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.